True North Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From True North Therapeutics, Inc.
Star And Portfolio Firm Electra Roll Out With Focus On Rare Immunologic Disease
Star will employ a hub-and-spoke model to launch portfolio companies focused on specific biological areas. The first company, Electra, will emphasize unmet medical needs and therapies that can address multiple diseases.
Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
Sanofi Stunned As FDA Says No To CAD Drug Sutimlimab
The French major's hopes for launching its rare blood disorder drug sutimlimab soon have been scuppered by a complete response letter from the FDA after inspecting a third-party facility responsible for making the first-in-class therapy.
Appointments: Amgen, Sirnaomics, Pandion, Purdue, Cardurion, OncoSec Make Senior Hires
Senior executives are to depart Gilead Sciences, Bristol-Myers Squibb and Amgen, while C-suite and board hires have been reported at Sirnaomics, Pandion, Purdue Pharma, Cardurion and OncoSec.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.